Abstract
Objective: The objective of this study is to assess the antitumor effects of hederagenin (HDG) in liver cancer (LC) cells and explore the related mechanisms.
Materials and Methods: HepG2 cells were treated with HDG and cisplatin, respectively. The CCK8 assay was used to detect cell activity, DAPI staining was used to detect the proportion of living cells, TUNEL assay to detect the proportion of apoptotic cells, flow cytometry to detect the membrane potential, fluoroscopic electron microscopy to detect microstructural changes to the mitochondrial, and western blot analysis and high-content screening to detect apoptosisrelated proteins.
Results: Treatment with HDG inhibited the growth of HepG2 cells, decreased the proportion of viable cells, increased the proportion of apoptotic cells, and significantly increased the proportion of cells in the G1 phase. Fluorescence staining showed that HDG damaged the mitochondria of HepG2 cells and significantly decreased the number of mitochondria. Flow cytometry showed that HDG decreased the mitochondrial membrane potential of HepG2 cells. Observations by electron microscopy showed that HDG caused swelling and vacuole formation of the mitochondria of HepG2 cells. HDG significantly reduced the average fluorescence intensity of Bcl-2 in HepG2 cells and significantly increased that of the pro-apoptosis proteins Bax, Cytochrome-c, and Caspase-3.
Conclusion: HDG induced apoptosis of HepG2 cells via the mitochondrial pathway.
Graphical Abstract
[http://dx.doi.org/10.1016/j.jhep.2021.04.049] [PMID: 33992698]
[http://dx.doi.org/10.2147/DDDT.S95275] [PMID: 26792982]
[http://dx.doi.org/10.3390/nu10030283] [PMID: 29495626]
[http://dx.doi.org/10.1039/C8RA03666G] [PMID: 35539158]
[http://dx.doi.org/10.1038/s41419-020-02880-5] [PMID: 32792495]
[http://dx.doi.org/10.1155/2017/5498908] [PMID: 29456786]
[http://dx.doi.org/10.3389/fphar.2022.895738] [PMID: 36034875]
[http://dx.doi.org/10.3390/cells11010030] [PMID: 35011593]
[http://dx.doi.org/10.3892/ijmm.2019.4188] [PMID: 31115493]
[http://dx.doi.org/10.1038/s41598-020-71118-3] [PMID: 32843660]
[http://dx.doi.org/10.1155/2022/2026865] [PMID: 35529935]
[http://dx.doi.org/10.1208/s12248-019-0301-6] [PMID: 30783799]
[http://dx.doi.org/10.3390/ijms22136923] [PMID: 34203270]
[http://dx.doi.org/10.2147/IJN.S373282] [PMID: 36419717]
[http://dx.doi.org/10.1016/j.ejpb.2015.03.018] [PMID: 25813885]
[http://dx.doi.org/10.21873/invivo.12542] [PMID: 34410947]
[http://dx.doi.org/10.1158/0008-5472.CAN-20-3134] [PMID: 33762357]
[http://dx.doi.org/10.1016/j.fct.2021.112351] [PMID: 34171418]
[http://dx.doi.org/10.3892/or.2020.7517] [PMID: 32323800]